MBX Biosciences Inc (MBX) Expected Move

Tracking the MBX expected move helps you see how far MBX Biosciences Inc's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. MBX Biosciences Inc's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the MBX expected move for this week's options, in real time.

The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For MBX, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The MBX expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks MBX Biosciences Inc is unlikely to go.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.

In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the MBX expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The MBX Biosciences Inc expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about MBX.